MX2022000074A - Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro. - Google Patents

Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.

Info

Publication number
MX2022000074A
MX2022000074A MX2022000074A MX2022000074A MX2022000074A MX 2022000074 A MX2022000074 A MX 2022000074A MX 2022000074 A MX2022000074 A MX 2022000074A MX 2022000074 A MX2022000074 A MX 2022000074A MX 2022000074 A MX2022000074 A MX 2022000074A
Authority
MX
Mexico
Prior art keywords
skin
brain
disclosed
exosomes
subject
Prior art date
Application number
MX2022000074A
Other languages
English (en)
Inventor
Daniel Gallego-Perez
Natalia Higuita-Castro
William Lawrence
Diego Alzate Correa
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of MX2022000074A publication Critical patent/MX2022000074A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)

Abstract

Tal como se describe en la presente, la piel puede enviar señales al cerebro en la forma de exosomas, que en la presente se denomina "eje piel-cerebro"; por lo tanto, en la presente se describe un método para diagnosticar una enfermedad, trastorno o lesión cerebral en un sujeto que implica aislar los exosomas del sujeto y analizar los exosomas para determinar la presencia de uno o más biomarcadores de la enfermedad, trastorno o lesión; también se describen métodos para tratar un sujeto con una enfermedad, trastorno o lesión cerebral que implican modificar la piel del sujeto para producir exosomas terapéuticos; también se describen métodos para recoger exosomas producidos por la piel y cargarlos con carga terapéutica que pueda tratar una o más enfermedades, trastornos o lesiones del cerebro; también se describe en la presente un método para reducir la liberación exosomal de la piel para reducir el tráfico al cerebro.
MX2022000074A 2019-07-02 2020-07-02 Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro. MX2022000074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869788P 2019-07-02 2019-07-02
PCT/US2020/040721 WO2021003403A1 (en) 2019-07-02 2020-07-02 Neurodegenerative disease therapies utilizing the skin-brain axis

Publications (1)

Publication Number Publication Date
MX2022000074A true MX2022000074A (es) 2022-04-06

Family

ID=74100999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000074A MX2022000074A (es) 2019-07-02 2020-07-02 Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.

Country Status (11)

Country Link
US (1) US20220244275A1 (es)
EP (1) EP3993776A4 (es)
JP (2) JP2022538834A (es)
KR (1) KR20220029665A (es)
CN (1) CN114423413A (es)
AU (1) AU2020299633A1 (es)
BR (1) BR112021026641A2 (es)
CA (1) CA3144965A1 (es)
IL (1) IL289485A (es)
MX (1) MX2022000074A (es)
WO (1) WO2021003403A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107475B (zh) * 2020-08-28 2024-05-14 复旦大学附属华山医院 Tmf1多态性位点作为基因标志物以及和甲氨蝶呤联合的银屑病试剂盒
CN115245521B (zh) * 2021-04-28 2024-07-26 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的滴鼻剂及其在治疗脑神经血管疾病中的应用
US20240263237A1 (en) * 2021-05-28 2024-08-08 La Jolla Institute For Immunology T cell transcriptomic profiles in parkinson's disease, and methods and uses thereof
CN113774058B (zh) * 2021-08-26 2023-08-04 中国药科大学 血清中脑部细胞来源的外泌体环状rna作为阿尔兹海默症诊断标志物的应用
EP4458369A1 (en) * 2021-12-29 2024-11-06 Shanghai Quietd Biotechnology Co., Ltd. Use of proton pump modulator in preparing reagent
JP7492757B2 (ja) * 2022-03-22 2024-05-30 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
WO2023182507A1 (ja) * 2022-03-24 2023-09-28 北海道公立大学法人 札幌医科大学 薬学的組成物、間葉系幹細胞の三次元培養物の製造方法、エクソソームの製造方法、および薬学的組成物の製造方法
CN116716351B (zh) * 2023-03-30 2024-02-23 湖北天勤生物技术研究院有限公司 用于构建食蟹猴阿尔兹海默症模型的组合物及其应用和构建方法
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615212B2 (en) * 2004-02-26 2009-11-10 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
EP2247299A4 (en) * 2007-12-21 2012-06-06 Univ Rochester MOLECULAR TARGETS FOR THE TREATMENT OF INFLAMMATION
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
WO2012162211A2 (en) * 2011-05-20 2012-11-29 Rush University Medical Center Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor gw4869 for degenerative neurological disorders
EP3527670B1 (en) * 2013-03-15 2023-10-18 Beth Israel Deaconess Medical Center, Inc. Mirna biogenesis in exosomes for diagnosis and therapy
WO2015006705A2 (en) * 2013-07-11 2015-01-15 The Trustees Of Columbia University In The City Of New York Micrornas that silence tau expression
US20170014450A1 (en) * 2014-02-28 2017-01-19 Exosome Sciences, Inc. Brain specific exosome based diagnostics and extracorporeal therapies
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
US20190049467A1 (en) * 2015-11-20 2019-02-14 Exosorme Sciences, Inc. Exosomal tau as a biomarker for brain disorders
CA3046982A1 (en) * 2016-12-22 2018-06-28 Ohio State Innovation Foundation Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
CA3065999A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Also Published As

Publication number Publication date
IL289485A (en) 2022-02-01
BR112021026641A2 (pt) 2022-03-22
KR20220029665A (ko) 2022-03-08
US20220244275A1 (en) 2022-08-04
CA3144965A1 (en) 2021-01-07
JP2024138242A (ja) 2024-10-08
EP3993776A4 (en) 2023-08-30
WO2021003403A1 (en) 2021-01-07
EP3993776A1 (en) 2022-05-11
JP2022538834A (ja) 2022-09-06
CN114423413A (zh) 2022-04-29
AU2020299633A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2022000074A (es) Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
WO2016210372A3 (en) Methods to treat neurological diseases
WO2019099639A8 (en) Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
BR112018008069A2 (pt) métodos de tratamento de doenças neurodegenerati-vas usando terapia gênica para retardar o início e progressão da doença ao mesmo tempo em que fornece proteção cognitiva
NZ751690A (en) Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
WO2015033319A3 (en) Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease
WO2019236750A3 (en) Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
PH12021550176A1 (en) Method for treating epilepsy
MX2022001008A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
IL312649A (en) A system and method for the diagnosis and treatment of biological arrhythmias
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
Rocca et al. Functional MRI to study brain plasticity in clinical neurology
MX2023010970A (es) Metodos de clasificacion y tratamiento de pacientes.
MX2021010467A (es) Biomarcadores para dolencias articulares y usos de estos.
EP4030995A4 (en) METHODS FOR DIAGNOSING AND TREATING NEURONAL DISEASES
Onugoren et al. Conjoint occurrence of GABAB receptor antibodies in Lambert–Eaton myasthenic syndrome with antibodies to the voltage gated calcium channel
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
IL290048A (en) A method and device for reducing the risk, and identifying the existence of neural injury of a human fetus before and during birth
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.
EP3452832A4 (en) METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF DISEASES OR INJURIES OF THE NERVOUS SYSTEM
GB202011522D0 (en) Neuromodulation for the treatment of circulatory system diseases
WO2019118951A3 (en) Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system